Service d'Oncologie Médicale, Groupe Hospitalier Pitié Salpêtrière, Paris, France.
Crit Rev Oncol Hematol. 2012 Dec;84(3):301-13. doi: 10.1016/j.critrevonc.2012.05.002. Epub 2012 Jun 17.
The identification of predictive factors of response is critical for the development and appropriate use of anti-cancer agents. The evaluation of biomarkers is usually performed by analyzing the primary tumor tissues but this approach does not take into account potential discrepancies between primary tumor and secondary lesions. This review proposes to describe currently available data regarding differential expression of established biomarkers between primary tumor and matched metastasis. In light of recent data, the need of iterative biopsies in metastatic setting has been suggested but technical and methodological limits in such analyses should not be ignored and this strategy cannot be definitively validated. Complementary studies are still needed since the question of spatial and temporal variability of biomarkers in solid tumors is clearly a key issue in an era where personalized therapy is strongly advocated by clinicians, researchers and patients.
确定预测反应的因素对于抗癌药物的开发和合理应用至关重要。生物标志物的评估通常通过分析原发性肿瘤组织来进行，但这种方法没有考虑到原发性肿瘤和继发性病变之间可能存在的差异。本综述旨在描述目前关于原发性肿瘤和匹配转移灶之间已建立的生物标志物表达差异的可用数据。鉴于最近的数据，有人建议在转移性疾病中进行反复活检，但不应忽视此类分析中的技术和方法学限制，并且不能明确验证这种策略。仍需要进行补充研究，因为在个体化治疗强烈受到临床医生、研究人员和患者推崇的时代，实体瘤中生物标志物的空间和时间变异性问题显然是一个关键问题。
